Abbott SCSPENDING
Nevro SCSPENDING
Cyclosporiasis OutbreakPENDING
Dupixent CTCLNEW MDL
Boston Sci. SCSNEW MDL
AI Chatbot Harm
NEWMONITOR
Roundup
ACTIVE
AFFF
ACTIVE
Depo-Provera
QUIET
Talc
QUIET
PFAS
ACTIVE
NEC Formula
ACTIVE
Bard Hernia Mesh
QUIET
Covidien Hernia Mesh
ACTIVE
Camp Lejeune
ACTIVE
Paraquat
ACTIVE
Social Media
ACTIVE
PowerPort
ACTIVE
AngioDynamics Port
ACTIVE
EtO Sterilization
ACTIVE
Hair Relaxer
ACTIVE
Paragard
ACTIVE
Suboxone Teeth
ACTIVE
Uber Assault
ACTIVE
Lyft Assault
ACTIVE
Ozempic Gastroparesis
ACTIVE
Ozempic NAION
MONITOR
Church Abuse
ACTIVE
1,4-Dioxane
MONITOR
Hotel Trafficking
ACTIVE
Boy Scouts
QUIET
LDS Abuse
ACTIVE
Keytruda
ACTIVE
Tylenol
ACTIVE
Assembly of God
ACTIVE
Video Game Addiction
ACTIVE
CA Women's Prisons
ACTIVE
Zantac
ACTIVE
ByHeart Formula
MONITOR
Cartiva
MONITOR
Roblox
ACTIVE
Sports Betting
MONITOR
Baby Food Metals
QUIET
Benzene Litigation
ACTIVE
Discord Abuse
ACTIVE
Social Media Sextortion
MONITOR
UPF Litigation
MONITOR
47Tracked
28Active
3Pending
Navigation
Abbott SCSPENDING
Nevro SCSPENDING
Cyclosporiasis OutbreakPENDING
Dupixent CTCLNEW MDL
Boston Sci. SCSNEW MDL
AI Chatbot Harm
NEWMONITOR
Roundup
ACTIVE
AFFF
ACTIVE
Depo-Provera
QUIET
Talc
QUIET
PFAS
ACTIVE
NEC Formula
ACTIVE
Bard Hernia Mesh
QUIET
Covidien Hernia Mesh
ACTIVE
Camp Lejeune
ACTIVE
Paraquat
ACTIVE
Social Media
ACTIVE
PowerPort
ACTIVE
AngioDynamics Port
ACTIVE
EtO Sterilization
ACTIVE
Hair Relaxer
ACTIVE
Paragard
ACTIVE
Suboxone Teeth
ACTIVE
Uber Assault
ACTIVE
Lyft Assault
ACTIVE
Ozempic Gastroparesis
ACTIVE
Ozempic NAION
MONITOR
Church Abuse
ACTIVE
1,4-Dioxane
MONITOR
Hotel Trafficking
ACTIVE
Boy Scouts
QUIET
LDS Abuse
ACTIVE
Keytruda
ACTIVE
Tylenol
ACTIVE
Assembly of God
ACTIVE
Video Game Addiction
ACTIVE
CA Women's Prisons
ACTIVE
Zantac
ACTIVE
ByHeart Formula
MONITOR
Cartiva
MONITOR
Roblox
ACTIVE
Sports Betting
MONITOR
Baby Food Metals
QUIET
Benzene Litigation
ACTIVE
Discord Abuse
ACTIVE
Social Media Sextortion
MONITOR
UPF Litigation
MONITOR
47Tracked
28Active
3Pending
LexGenius Logo
LexGeniusYour Edge in Mass Litigation
PricingDaily DocketTrack litigations freeSign in
LexGenius

LexGenius

Your Edge in Mass Litigation

DisclaimerAcceptable UseTermsPrivacyCookie PolicySupport

© 2026 LexGenius. All rights reserved.

← All Briefs

Daily Intelligence Brief

Monday, July 20, 2026

Passenger-Assault Intake Leads a Broad Filing Surge

Passenger-assault claims supplied the week’s clearest filing surge, with Uber Passenger Sexual Assault (3084) logging 88 matters as Keller Postman LLC and Murphy Law Firm led the filer mix. Environmental and pharmaceutical cases formed the next concentrated tier: AFFF Personal Injury (2873) drew 69 filings through Krentsel & Guzman LLP and Ashcraft Gerel LLP, while Suboxone (3092) added 51 behind Peiffer Wolf. Hair Relaxer (3060) generated 45 filings led by Singleton Schreiber LLP, showing continued intake in established consumer-product litigation rather than a one-docket spike. The diabetes-drug docket Ozempic (3094) contributed 14 more cases, with Flint Cooper leading its filer group. See the full filing feed and firm-level breakdowns here.

POTW PFAS Study Creates a New Environmental Evidence Marker

On July 20, 2026, the POTW Influent PFAS Study marked a regulatory data-collection milestone for PFAS disputes by focusing attention on wastewater entering publicly owned treatment works. The study adds a current federal reference point for source attribution, exposure mapping, and allocation disputes involving public wastewater systems. For AFFF Personal Injury (2873), influent data may bear on competing theories about upstream PFAS inputs and environmental pathways, without resolving causation or liability in any individual action. Its practical importance lies in the potential evidentiary record available before expert-discovery disputes mature.

Gut-Microbiota Research Adds Context for Ultra-Processed-Food Claims

On July 18, 2026, Food Industry Engineering Is Less Important Than Access to Gut Microbiota-Accessible Foods for Preventing Chronic Disease added a peer-reviewed research development to the debate over dietary processing and chronic disease. The paper centers on access to foods that support gut-microbiota activity rather than food-industry engineering, a distinction relevant to proposed mechanisms of harm. It does not establish liability or resolve any pending product-liability claim. But the publication supplies a current scientific marker for counsel testing expert theories in ultra-processed-food litigation.

Generated by LexGenius Feed. Signals sourced from PACER federal court dockets, FDA/OpenFDA adverse event database, Federal Register, PubMed, and Google News.